Form 4: Cingulate Inc. Executive Matthew Brams Reports Stock Option Grant

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reports the acquisition of stock options exercisable for 63,324 shares of common stock.

Summary

• Matthew Brams, the EVP and Chief Medical Officer of Cingulate Inc. (CING), filed a Form 4 on June 13, 2024, reporting a transaction.
• On June 11, 2024, Brams acquired stock options to purchase 63,324 shares of Cingulate Inc. common stock at an exercise price of $1.18.
• The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, contingent on stockholder approval of Amendment No. 1 to the company's 2021 Omnibus Equity Incentive Plan, which was obtained on June 11, 2024.
• The options vest with 50% vesting six months from the grant date and the remaining 50% vesting in equal monthly installments over the following 30 months.
• Following the reported transaction, Brams directly owns 63,324 derivative securities in the form of stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The option grant itself is a positive incentive for the executive, but the disclosure is routine.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of the options is typical, with a combination of time-based and performance-based vesting conditions often used.

Stakeholder Impact

• The stock option grant incentivizes the executive to improve company performance, potentially benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, Cingulate Inc., executive compensation, beneficial ownership, CING, Matthew Brams